# Where Pediatric Cannabinoid Evidence Is Strong, Where It Is Thin, and Where It Does Not Exist At All

> **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637)
> **Publisher:** CED Clinic (https://cedclinic.com)
> **Canonical URL:** https://cedclinic.com/medical-cannabis-for-children-what-evidence-supports/
> **Published:** 2026-09-04T22:52:18-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:40:01-04:00
> **Clinical Summary:** Medical cannabis for children: pharmaceutical CBD has randomized evidence in three epilepsy syndromes. Almost everything else is weaker than parents hear.

---

CED Clinical Relevance #61High Safety RelevanceParents of children with serious neurological conditions encounter confident claims about cannabis in places where no trial evidence exists. Drawing the line between what randomized trials have shown and what they have not is the most useful thing a physician can offer that conversation.

Pharmaceutical cannabidiol has randomized, placebo-controlled evidence in three specific epilepsy syndromes, and that evidence is good. Outside those syndromes the picture changes sharply, and the gap between what parents are told and what has been tested is wide enough to be worth mapping carefully.

Clinical Insight | CED Clinic

In a placebo-controlled randomized trial in tuberous sclerosis complex, cannabidiol at 25 mg per kilogram per day reduced seizures by 48.6 percent compared with 26.5 percent on placebo, a 30.1 percentage point difference. Nearly one in five children taking cannabidiol had elevated liver transaminases and none on placebo did.

In the largest randomized trial of cannabinoids in autism, 150 participants aged 5 to 21, the registered primary behavioral outcome did not differ between groups. The investigators described the efficacy evidence as mixed and insufficient.

Pediatric MedicineCannabidiolEpilepsy[Autism Spectrum Disorder](https://cedclinic.com/cbd-gummies-autism-symptoms-clinical/)Clinical Research
AudienceParents, caregivers, and clinicians caring for childrenPrimary TopicEvidence for cannabinoid treatment in pediatric patientsSource[Read the full source](https://doi.org/10.1001/jamaneurol.2020.4607)
Why This Matters

A parent researching cannabis for a child with seizures, autism, chronic pain, or attention problems will find the same confident tone applied to all four, and only one of them has randomized evidence behind it. Sorting those apart is the difference between an informed specialist conversation and an expensive detour.

The safety information is also frequently understated. Cannabidiol in the pediatric epilepsy trials was not a gentle intervention: it produced diarrhea, somnolence, liver enzyme elevations, and trial discontinuations at rates that any parent deserves to see before starting.

The Solid Ground: Three Epilepsy Syndromes

The evidence that changed pediatric practice came from randomized, placebo-controlled trials of a pharmaceutical cannabidiol oral solution in specific, severe, drug-resistant epilepsies. In Dravet syndrome, Orrin Devinsky and colleagues randomized 120 children and young adults to cannabidiol at 20 mg per kilogram per day or placebo, added to existing antiepileptic treatment. Median convulsive seizure frequency fell from 12.4 to 5.9 per month on cannabidiol, compared with 14.9 to 14.1 on placebo, an adjusted median difference of 22.8 percentage points.

The trial in tuberous sclerosis complex, led by Elizabeth Thiele and published in *JAMA Neurology*, randomized 224 patients aged 1 to 65 with a median age of 11.4 years to cannabidiol at 25 or 50 mg per kilogram per day or placebo for 16 weeks. Seizure reduction was 48.6 percent at the lower dose, 47.5 percent at the higher dose, and 26.5 percent on placebo. The reduction relative to placebo was 30.1 percentage points for the 25 mg per kilogram group.

These results are real and they are also specific. The conditions are rare and severe, the product is a standardized pharmaceutical preparation rather than a cannabis extract, dosing is by body weight, and treatment is added to existing antiepileptic medication under neurology supervision. Every one of those conditions is part of what was tested.

The epilepsy trial evidence is covered in more detail in our companion piece on recognizing seizures, linked below, so this page focuses on where the evidence stops.

Autism: The Most Common Question, the Weakest Answer

Autism is where parents most often encounter enthusiastic claims, and it is where the best-designed trial produced the most equivocal result. Adi Aran and colleagues at Shaare Zedek Medical Center in Jerusalem randomized 150 participants aged 5 to 21 with autism spectrum disorder to a whole-plant cannabis extract with cannabidiol and THC in a 20 to 1 ratio, a purified cannabinoid preparation at the same ratio, or placebo, for 12 weeks, followed by washout and crossover.

The registered primary outcome, change in total score on the Home Situation Questionnaire adapted for autism, did not differ between groups. On the co-primary Clinical Global Impression measure, disruptive behavior was rated much or very much improved in 49 percent on whole-plant extract against 21 percent on placebo. Median Social Responsiveness Scale scores improved by 14.9 points on whole-plant extract against 3.6 on placebo. Somnolence was reported by 28 percent and decreased appetite by 25 percent on whole-plant extract, against 8 percent and 15 percent on placebo.

The authors’ own conclusion is the fairest summary available: the preparations were well tolerated, evidence for efficacy was mixed and insufficient, and further testing is recommended. A parent should read a split between a null primary outcome and positive secondary outcomes as a reason to keep studying the question, not as a demonstration that it works.

The same research group examined sleep outcomes in the same 150 participants using the Children’s Sleep Habits Questionnaire and found that cannabinoid treatment was not superior to placebo on any measured aspect of sleep, including bedtime resistance, sleep-onset delay, and sleep duration. Sleep improvement is one of the most commonly claimed benefits in this population and it did not separate from placebo.

Where There Is Essentially Nothing

For pediatric attention deficit hyperactivity disorder, no adequately powered randomized trial of cannabis or cannabinoids exists. Claims that cannabis improves concentration or reduces hyperactivity in children rest on case reports, parent surveys, and extrapolation from adult data that is itself thin.

For pediatric chronic pain, the same gap applies. Cannabinoids have been studied in adults with chronic pain extensively and with mixed results, and that literature does not transfer to children, whose pain conditions, developmental stage, and risk profile differ substantially.

For symptom control in pediatric cancer, including nausea and appetite, the evidence base is small and largely observational. This is an area where a pediatric oncology or palliative care team may reasonably consider a cannabinoid in a specific case, and that decision belongs inside that team rather than being made by a family independently.

The absence of evidence in these areas is not proof of absence of benefit. It does mean that any product used for these purposes in a child is being used without the kind of testing the epilepsy indications received, and a parent should know that is the situation rather than assume the research exists somewhere.

The Safety Picture Deserves More Space Than It Usually Gets

In the tuberous sclerosis trial, diarrhea occurred in 31 percent of the 25 mg per kilogram group and 56 percent of the 50 mg per kilogram group, against 25 percent on placebo. Somnolence occurred in 13 and 26 percent respectively, against 9 percent. Eight patients in the lower-dose group and ten in the higher-dose group discontinued because of adverse events, compared with two on placebo. Twenty-eight patients taking cannabidiol, or 18.9 percent, had elevated liver transaminases, and none on placebo did.

The Dravet trial reported the same pattern: diarrhea, vomiting, fatigue, fever, somnolence, and abnormal liver function tests occurred more often on cannabidiol than placebo, and there were more withdrawals from the cannabidiol group.

Those numbers are from a monitored trial with a standardized product, scheduled laboratory testing, and specialist oversight. A retail product used at home has none of those safeguards. Cannabidiol also interacts with antiepileptic medications, which is one reason liver monitoring is part of the protocol rather than an optional extra.

Separately, unintentional exposure is a documented pediatric hazard that has grown quickly. A retrospective analysis of National Poison Data System records published in *Pediatrics* found 7,043 reported exposures to edible [cannabis products](https://cedclinic.com/cbd-gummies-daily-use-evidence-men/) in children under 6 between 2017 and 2021, rising from 207 cases in 2017 to 3,054 in 2021. Of cases followed to a known outcome, 70 percent involved central nervous system depression, and 22.7 percent of all reported cases were admitted to hospital. Nearly all exposures, 97.7 percent, occurred in a residential setting.

How a Parent Should Actually Proceed

If the child has drug-resistant epilepsy, particularly Dravet syndrome, Lennox-Gastaut syndrome, or tuberous sclerosis complex, the conversation belongs with a pediatric epileptologist, and the product in question is a prescribed pharmaceutical cannabidiol formulation with weight-based dosing and scheduled liver monitoring. That is a specialist referral, and it is a reasonable one to ask for.

If the child has autism, attention problems, chronic pain, or another condition, the honest framing is that a family would be trying something that has not been shown to work in a properly controlled trial, using a product that was not the one tested, without the monitoring the trials included. That may still be a conversation worth having with the child’s specialist, and it should happen with that specialist rather than around them.

Bring the specific product to any such conversation. Content varies between preparations, cannabidiol interacts with several medications a child with a neurological condition is likely to be taking, and the trial products were standardized in ways retail products generally are not.

And regardless of any of the above, store cannabis products where a young child cannot reach them. The poison center data describe thousands of preventable hospitalizations in children under six, almost all of them occurring at home.

Study SnapshotAnchor TrialAdd-on Cannabidiol Treatment for Drug-Resistant Seizures in Tuberous Sclerosis Complex: A Placebo-Controlled Randomized Clinical Trial (GWPCARE6)DesignDouble-blind, placebo-controlled randomized trial at 46 sites across six countries; 16 weeks of treatmentParticipants224 randomized of 255 screened; median age 11.4 years, range 1.1 to 56.8; 41.5% femaleInterventionOral cannabidiol 25 mg/kg/day or 50 mg/kg/day versus matched placebo, added to existing antiepileptic medicationPrimary OutcomeSeizure reduction 48.6% at 25 mg/kg/day, 47.5% at 50 mg/kg/day, 26.5% on placebo; reduction versus placebo 30.1 percentage points at the lower dose (P < .001)Adverse EventsDiarrhea 31% and 56% versus 25% placebo; somnolence 13% and 26% versus 9%; elevated liver transaminases in 18.9% of cannabidiol patients and none on placeboJournalJAMA Neurology 2021;78(3):285-292PMID / DOI33346789 / 10.1001/jamaneurol.2020.4607Dravet ComparisonDevinsky et al., New England Journal of Medicine 2017;376(21):2011-2020; 120 participants; median convulsive seizures fell 12.4 to 5.9 on cannabidiol versus 14.9 to 14.1 on placebo (PMID 28538134)Autism TrialAran et al., Molecular Autism 2021;12(1):6; 150 participants aged 5 to 21; registered primary outcome not different between groups; authors call efficacy evidence mixed and insufficient (PMID 33536055)Exposure SurveillanceTweet et al., Pediatrics 2023;151(2):e2022057761; 7,043 edible cannabis exposures in children under 6 from 2017 to 2021, rising from 207 to 3,054 annual cases (PMID 36594224)
How Strong Is This Evidence?

The epilepsy evidence is strong and unusual for this field: multiple independent randomized, placebo-controlled trials, hundreds of participants, prespecified primary endpoints, and results that supported regulatory approval. Very little else in cannabinoid medicine reaches that standard.

The autism evidence is moderate in quality and weak in result. A 150-participant randomized crossover trial is a serious study, and its registered primary outcome was null. That combination is more informative than a positive uncontrolled study, and it points away from confident claims.

Where This Paper Deserves Skepticism

Positive secondary outcomes in a trial whose primary outcome was null should be treated as hypothesis-generating. The autism trial reported improvement on clinician global impression and on a social responsiveness measure while the registered primary measure did not separate, which is a pattern that frequently fails to replicate.

The epilepsy trials also tested a specific pharmaceutical preparation at defined weight-based doses in narrowly defined syndromes. Generalizing from a 20 mg per kilogram per day standardized oral solution in Dravet syndrome to an over-the-counter product in a child with a different diagnosis is a much larger leap than it appears.

What This Paper Does Not Show

These trials do not show that cannabis helps children with attention deficit hyperactivity disorder, chronic pain, or most other pediatric conditions, because those trials have not been conducted at adequate size and rigor. Absence of evidence is not evidence of absence, and it is also not a basis for treatment.

They also do not show that cannabidiol is a low-risk intervention in children. Roughly one in five participants in the tuberous sclerosis trial developed elevated liver transaminases, and discontinuation for adverse events was several times higher than on placebo.

How This Fits With the Broader Clinical Conversation

Pediatric cannabinoid medicine is a useful case study in how a specific, well-run trial program can establish a genuine therapy while simultaneously creating a halo around a whole product category. The trials tested one molecule, in one formulation, in three syndromes. The marketing that followed tested nothing.

The distance between those two facts is where most pediatric cannabis decisions go wrong, and closing it is largely a matter of asking which product, which dose, and which trial.

Dr. Caplan’s Take

When a parent comes to me about a child, my first question is which condition and my second is which product. Those two answers determine almost everything, and they are usually the two things missing from whatever the family read before the appointment.

For a child with Dravet syndrome or Lennox-Gastaut or tuberous sclerosis, I am pointing toward a pediatric epileptologist and a prescription formulation with liver monitoring, and I say so without hedging. That pathway exists, it is well studied, and a family should not have to improvise it.

For autism, and this is the conversation I have most often, I try to be honest about the Aran trial rather than quote the part parents want to hear. The primary outcome was negative. Some secondary outcomes were not. That is a reason to want a better trial, and it is not a reason to start a child on a product at home.

The other thing I bring up whether or not anyone asks: lock the products away. The poison center numbers describe thousands of small children hospitalized after finding an edible at home, and that harm is entirely preventable.

Clinical Bottom Line

Pharmaceutical cannabidiol has randomized, placebo-controlled evidence in Dravet syndrome, Lennox-Gastaut syndrome, and tuberous sclerosis complex, as an add-on therapy under specialist supervision with liver monitoring. Outside those syndromes the evidence thins quickly: the largest autism trial had a null primary outcome, sleep outcomes did not separate from placebo, and for pediatric attention problems, chronic pain, and most other indications no adequate trial exists. The pathway for any child is specialist evaluation, never a product purchased on a parent’s own research.

What a Careful Reader Should Take Away

The word doing the most work in the strong evidence is pharmaceutical. What was tested was a standardized cannabidiol oral solution, dosed by body weight, added to existing antiepileptic medication, with scheduled laboratory monitoring, in three named syndromes. Strip away any of those conditions and you are no longer inside the evidence, whatever the product label says.

Evidence Interpretation Guide

Table of Contents

- [How to tell a tested therapy from a marketed one](#How_to_tell_a_tested_therapy_from_a_marketed_one)
- [Cannabinoids in Children, Seen From Eight Angles](#Cannabinoids_in_Children_Seen_From_Eight_Angles)[For the parent trying to sort claims from evidence](#For_the_parent_trying_to_sort_claims_from_evidence)
- [Name the boundary out loud](#Name_the_boundary_out_loud)
- [A null primary outcome is the headline](#A_null_primary_outcome_is_the_headline)
- [Generalization is where this goes wrong](#Generalization_is_where_this_goes_wrong)
- [Parent advocacy preceded the trials](#Parent_advocacy_preceded_the_trials)
- [What supervised treatment involves](#What_supervised_treatment_involves)
- [The trials pediatrics still needs](#The_trials_pediatrics_still_needs)
- [Packaging is a pediatric safety issue](#Packaging_is_a_pediatric_safety_issue)
- [Frequently Asked Questions](#Frequently_Asked_Questions)[Related](#Related)

## How to tell a tested therapy from a marketed one

The Research QuestionDoes add-on cannabidiol reduce seizures in children with drug-resistant epilepsy, and at what cost in adverse effects?The Patient QuestionMy child has a serious condition and I keep reading that cannabis helps. Is that true for my child?The Bottom LineThree epilepsy syndromes have randomized evidence for a pharmaceutical cannabidiol preparation. Autism has one large trial with a null primary outcome. Most other pediatric indications have no adequate trial at all.
CED Perspective Lens

## Cannabinoids in Children, Seen From Eight Angles

Where the pediatric evidence is strong, where it is equivocal, and where it is absent.

Lens OverviewRandomized placebo-controlled trials support pharmaceutical cannabidiol as add-on therapy in Dravet syndrome, Lennox-Gastaut syndrome, and tuberous sclerosis complex, while the largest autism trial reported a null primary outcome and most other pediatric indications have never been adequately tested.

#### For the parent trying to sort claims from evidence

Ask two questions about anything you read: which exact condition was studied, and which exact product. The strong pediatric evidence involves a prescription cannabidiol solution in three rare epilepsy syndromes, dosed by body weight with blood tests along the way.

If the claim you are reading does not match on both counts, it is an extrapolation rather than a finding, and it deserves a specialist’s opinion before anything else.

Lens takeawayWhich condition and which product. Those two questions resolve most of what you will read online.

#### Name the boundary out loud

Families arrive having read confident material that treats epilepsy, autism, pain, and attention as one category. Stating the boundary explicitly, with the trial names and the outcomes, does more for the conversation than a general caution.

Anticipate the drug interaction question. Cannabidiol interacts with several antiepileptic medications, and the child in front of you is likely to be taking one.

Lens takeawayDraw the line between the three tested syndromes and everything else, and do it specifically.

#### A null primary outcome is the headline

The autism trial registered its primary behavioral outcome in advance, and that outcome did not differ between groups. Secondary measures that moved are informative for designing the next study and are not a substitute for the result that was prespecified.

The companion sleep analysis in the same participants found no superiority over placebo on any measured sleep domain, which is worth weighing against how frequently sleep improvement is claimed.

Lens takeawayRead the prespecified outcome first. Everything after it is a hypothesis.

#### Generalization is where this goes wrong

The epilepsy trials enrolled narrowly defined syndromes, used a standardized product, and added it to existing medication. Each of those features limits how far the result travels.

A child with a different epilepsy, a different product, or no baseline antiepileptic regimen is outside the tested population, and the trial results say less about them than the enthusiasm suggests.

Lens takeawayThe stronger the trial, the more specific its conclusion. That is a feature, not a limitation.

#### Parent advocacy preceded the trials

Families of children with catastrophic epilepsy pushed this research forward well before randomized data existed, and the trials that followed largely vindicated the specific clinical question they raised.

That history explains both the credibility the field enjoys among parents and the risk that the same credibility gets extended to conditions where no equivalent research was ever done.

Lens takeawayThe epilepsy story earned its credibility. Borrowing it for other conditions is not warranted.

#### What supervised treatment involves

Weight-based dosing, titration over weeks, scheduled liver function testing, and review of interactions with existing antiepileptic medication. In the tuberous sclerosis trial, 18.9 percent of children on cannabidiol had elevated transaminases and none on placebo did.

Discontinuation for adverse effects was several times more common on cannabidiol than placebo, so the plan needs a route out as well as a route in.

Lens takeawayMonitoring is part of the therapy, not an optional accessory to it.

#### The trials pediatrics still needs

Adequately powered randomized trials in pediatric chronic pain and in attention deficit hyperactivity disorder do not exist, and the claims circulating about both would be straightforward to test.

For autism, a trial powered on the outcomes that moved in the Israeli study, with a prespecified primary endpoint chosen accordingly, is the logical next step the authors themselves recommended.

Lens takeawayThe questions parents ask most are the ones the field has tested least.

#### Packaging is a pediatric safety issue

Reported edible cannabis exposures in children under six rose from 207 in 2017 to 3,054 in 2021, with 70 percent of followed cases showing central nervous system depression and 22.7 percent admitted to hospital.

Nearly all of those exposures happened in a home. Child-resistant packaging and storage guidance address a documented and growing harm.

Lens takeawayStorage and packaging prevent a harm that is measurable, rising, and entirely avoidable.
Related Reading at CED ClinicContinue exploring the evidence[Pre-Seizure Symptoms: What an Aura Is and What a Prodrome Is](https://cedclinic.com/pre-seizure-symptoms-aura-warning-signs/)

Covers the epilepsy trial evidence and seizure recognition in more depth than this page does.

[Read the seizure guide](https://cedclinic.com/pre-seizure-symptoms-aura-warning-signs/)[CBD Oil and Autism: What a New Randomized Trial Shows](https://cedclinic.com/cbd-autism-social-cognition-randomized-trial/)

A closer look at a randomized trial in autism and what its outcome measures did and did not capture.

[See the autism trial](https://cedclinic.com/cbd-autism-social-cognition-randomized-trial/)[Running CBD and the Ketogenic Diet Together](https://cedclinic.com/cbd-and-ketogenic-diet-for-epilepsy-combination-study/)

What a 58-patient cohort found when two epilepsy treatments were combined in practice.

[Read the cohort study](https://cedclinic.com/cbd-and-ketogenic-diet-for-epilepsy-combination-study/)

Join the Conversation

Have a question about how this applies to your situation? [Ask Dr. Caplan](https://benjamincaplan.com/ask-dr-caplan)

Want to discuss this topic with other patients and caregivers? [Join the forum discussion](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/)

## Frequently Asked Questions

Is [medical cannabis](https://cedclinic.com/cbd-gummies-for-sexual-enhancement-evidence/) safe for children?

The question is better asked as which cannabinoid, for which condition, under whose supervision. Pharmaceutical cannabidiol has been tested in randomized trials in three severe epilepsy syndromes and carries real adverse effects: in the tuberous sclerosis trial, 18.9 percent of children had elevated liver transaminases, diarrhea and somnolence were common, and discontinuations were several times more frequent than on placebo. Retail cannabis products in children have not been tested this way.

Which childhood conditions have real evidence for cannabidiol?

Three drug-resistant epilepsy syndromes: Dravet syndrome, Lennox-Gastaut syndrome, and tuberous sclerosis complex. Each has randomized, placebo-controlled trial evidence using a standardized pharmaceutical cannabidiol oral solution added to existing antiepileptic medication. In the tuberous sclerosis trial, seizures fell 48.6 percent on cannabidiol at 25 mg per kilogram per day compared with 26.5 percent on placebo.

Does CBD help children with autism?

The largest randomized trial did not show that it does on its registered primary outcome. Aran and colleagues randomized 150 participants aged 5 to 21 and found no difference between groups on the prespecified behavioral measure, though some secondary measures favored the whole-plant extract. A companion analysis in the same participants found no superiority over placebo on any sleep measure. The authors called the efficacy evidence mixed and insufficient.

Can cannabis help a child with ADHD?

No adequately powered randomized trial has tested cannabis or cannabinoids for attention deficit hyperactivity disorder in children. Claims that cannabis improves concentration or reduces hyperactivity in this population rest on case reports, parent surveys, and extrapolation from limited adult data. Established treatments for pediatric ADHD have been tested against placebo, and a child with attention problems should be evaluated by a clinician rather than treated with an untested product.

What are the side effects of cannabidiol in children?

In the tuberous sclerosis trial, diarrhea occurred in 31 percent at the lower dose and 56 percent at the higher dose, against 25 percent on placebo, and somnolence in 13 and 26 percent against 9 percent. Elevated liver transaminases occurred in 18.9 percent of cannabidiol patients and none on placebo. The Dravet trial reported diarrhea, vomiting, fatigue, fever, somnolence, and abnormal liver function tests more often on cannabidiol.

Why does pharmaceutical CBD need liver monitoring?

Because liver enzyme elevations occurred in roughly one in five children in the tuberous sclerosis trial and in a meaningful proportion of the Dravet trial as well, and because cannabidiol interacts with several antiepileptic medications children with these syndromes are typically already taking. Scheduled laboratory testing is part of the protocol that produced the trial results, not an optional precaution added afterward.

How common is accidental cannabis poisoning in young children?

It has risen sharply. A National Poison Data System analysis published in Pediatrics found 7,043 reported edible cannabis exposures in children under six between 2017 and 2021, increasing from 207 cases in 2017 to 3,054 in 2021. Of cases followed to a known outcome, 70 percent involved central nervous system depression, 22.7 percent were admitted to hospital, and 97.7 percent occurred in a residential setting.

What should a parent do if they think cannabis might help their child?

Start with the child’s specialist rather than with a product. For drug-resistant epilepsy, ask for a referral to a pediatric epileptologist who can assess whether a prescription cannabidiol formulation is appropriate. For other conditions, bring the specific product and the specific claim to the treating clinician, because content varies between preparations and cannabidiol interacts with medications many of these children already take.

 

### Related

---

### Verification & Medical Governance

- **Lead Clinical Author:** Benjamin Caplan, MD
- **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House).
- **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`).
- **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/).
- **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637).
- **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).